share_log

Needham Reiterates Buy on Intra-Cellular Therapies, Maintains $100 Price Target

Benzinga ·  Oct 30, 2024 20:17  · Ratings

Needham analyst Ami Fadia reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and maintains $100 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment